FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2009366752> ?p ?o ?g. }

• W2009366752 endingPage "456" @default.
• W2009366752 startingPage "446" @default.
• W2009366752 abstract "Background Age-related macular degeneration (AMD) is a progressive disease that results in loss of central vision, significant functional impairment, and a subsequent heavy socioeconomic burden. AMD treatments delay disease progression, improve patient outcomes, and reduce resource use associated with visual impairment, however, in a varying way concerning costs and effects. Objective The purpose of this study was to investigate the cost effectiveness of ranibizumab compared with verteporfin photodynamic therapy, pegaptanib sodium, and best supportive care for the treatment of AMD in Greece. Methods A 6-state Markov model was constructed according to patient visual acuity in the better-seeing eye. Data on effectiveness were derived from randomized controlled trials evaluating the outcomes of ranibizumab versus alternative AMD treatments. Resource utilization reflected the Greek health care setting and was defined by a panel of experts. All treatments were administered for a 2-year period and evaluated during a 10-year time frame from a third-party payer perspective and discounted at 3.5% per annum. Results Estimated mean 10-year direct costs of treatment in the ranibizumab arm ranged from €23,733 to €31,795 (2011 Euros), with a projected gain of 4.50 to 4.74 quality-adjusted life years (QALYs) or 2.97 to 4.47 vision years, depending on type of lesion. For predominantly classic lesions, the cost per QALY gained with ranibizumab was estimated at €6444/QALY (95% uncertainty interval [UI], €−30,403/QALY to €44,524/QALY), €15,344 (95% UI, €−11,433 to €53,554) and dominant relative to photodynamic therapy, best supportive care, and pegaptanib, respectively. Corresponding ratios for patients with minimally classic lesions were €24,580/QALY (95% UI, €−5580/QALY to €76,229/QALY) and €13,112/QALY (95% UI, €−3839/QALY to €37,527/QALY) for ranibizumab relative to best supportive care and pegaptanib, and for patients with occult lesions were estimated at €19,407/QALY (95% UI, €−1486 to €46,434) and €28,561/QALY (95% UI, €6143 to 73,431), respectively. Sensitivity analysis provided robust results in all cases. Conclusion Ranibizumab can be a cost-effective option for the treatment of AMD compared with selected alternatives in the Greek health care setting." @default.
• W2009366752 created "2016-06-24" @default.
• W2009366752 creator A5001885893 @default.
• W2009366752 creator A5028623898 @default.
• W2009366752 creator A5052837407 @default.
• W2009366752 creator A5072838496 @default.
• W2009366752 creator A5073816018 @default.
• W2009366752 creator A5085973962 @default.
• W2009366752 date "2012-02-01" @default.
• W2009366752 modified "2023-09-26" @default.
• W2009366752 title "Cost-Effectiveness Analysis of Ranibizumab versus Verteporfin Photodynamic Therapy, Pegaptanib Sodium, and Best Supportive Care for the Treatment of Age-Related Macular Degeneration in Greece" @default.
• W2009366752 cites W1487528435 @default.
• W2009366752 cites W1802218256 @default.
• W2009366752 cites W1907606899 @default.
• W2009366752 cites W1977141020 @default.
• W2009366752 cites W1989832037 @default.
• W2009366752 cites W1990289864 @default.
• W2009366752 cites W1993476147 @default.
• W2009366752 cites W1995086395 @default.
• W2009366752 cites W1996401369 @default.
• W2009366752 cites W2001246020 @default.
• W2009366752 cites W2004273134 @default.
• W2009366752 cites W2016584341 @default.
• W2009366752 cites W2019119611 @default.
• W2009366752 cites W2030334080 @default.
• W2009366752 cites W2040380890 @default.
• W2009366752 cites W2044558504 @default.
• W2009366752 cites W2061382057 @default.
• W2009366752 cites W2075634939 @default.
• W2009366752 cites W2085442615 @default.
• W2009366752 cites W2085712747 @default.
• W2009366752 cites W2094512367 @default.
• W2009366752 cites W2094945298 @default.
• W2009366752 cites W2101421486 @default.
• W2009366752 cites W2111157054 @default.
• W2009366752 cites W2119756876 @default.
• W2009366752 cites W2124415048 @default.
• W2009366752 cites W2162119052 @default.
• W2009366752 cites W2598520882 @default.
• W2009366752 cites W2915852396 @default.
• W2009366752 cites W4240791162 @default.
• W2009366752 doi "https://doi.org/10.1016/j.clinthera.2012.01.005" @default.
• W2009366752 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22289279" @default.
• W2009366752 hasPublicationYear "2012" @default.
• W2009366752 type Work @default.
• W2009366752 sameAs 2009366752 @default.
• W2009366752 citedByCount "19" @default.
• W2009366752 countsByYear W20093667522013 @default.
• W2009366752 countsByYear W20093667522014 @default.
• W2009366752 countsByYear W20093667522015 @default.
• W2009366752 countsByYear W20093667522016 @default.
• W2009366752 countsByYear W20093667522018 @default.
• W2009366752 countsByYear W20093667522020 @default.
• W2009366752 countsByYear W20093667522022 @default.
• W2009366752 countsByYear W20093667522023 @default.
• W2009366752 crossrefType "journal-article" @default.
• W2009366752 hasAuthorship W2009366752A5001885893 @default.
• W2009366752 hasAuthorship W2009366752A5028623898 @default.
• W2009366752 hasAuthorship W2009366752A5052837407 @default.
• W2009366752 hasAuthorship W2009366752A5072838496 @default.
• W2009366752 hasAuthorship W2009366752A5073816018 @default.
• W2009366752 hasAuthorship W2009366752A5085973962 @default.
• W2009366752 hasConcept C112930515 @default.
• W2009366752 hasConcept C118487528 @default.
• W2009366752 hasConcept C126322002 @default.
• W2009366752 hasConcept C141071460 @default.
• W2009366752 hasConcept C168563851 @default.
• W2009366752 hasConcept C2776403814 @default.
• W2009366752 hasConcept C2776694085 @default.
• W2009366752 hasConcept C2777512022 @default.
• W2009366752 hasConcept C2777802072 @default.
• W2009366752 hasConcept C2778257484 @default.
• W2009366752 hasConcept C2781100027 @default.
• W2009366752 hasConcept C2781148688 @default.
• W2009366752 hasConcept C2781359195 @default.
• W2009366752 hasConcept C3019080777 @default.
• W2009366752 hasConcept C44249647 @default.
• W2009366752 hasConcept C64332521 @default.
• W2009366752 hasConcept C71924100 @default.
• W2009366752 hasConceptScore W2009366752C112930515 @default.
• W2009366752 hasConceptScore W2009366752C118487528 @default.
• W2009366752 hasConceptScore W2009366752C126322002 @default.
• W2009366752 hasConceptScore W2009366752C141071460 @default.
• W2009366752 hasConceptScore W2009366752C168563851 @default.
• W2009366752 hasConceptScore W2009366752C2776403814 @default.
• W2009366752 hasConceptScore W2009366752C2776694085 @default.
• W2009366752 hasConceptScore W2009366752C2777512022 @default.
• W2009366752 hasConceptScore W2009366752C2777802072 @default.
• W2009366752 hasConceptScore W2009366752C2778257484 @default.
• W2009366752 hasConceptScore W2009366752C2781100027 @default.
• W2009366752 hasConceptScore W2009366752C2781148688 @default.
• W2009366752 hasConceptScore W2009366752C2781359195 @default.
• W2009366752 hasConceptScore W2009366752C3019080777 @default.
• W2009366752 hasConceptScore W2009366752C44249647 @default.
• W2009366752 hasConceptScore W2009366752C64332521 @default.
• W2009366752 hasConceptScore W2009366752C71924100 @default.
• W2009366752 hasIssue "2" @default.
• W2009366752 hasLocation W20093667521 @default.

• next